Sourcing intelligence for professional aesthetic buyers

Request ISO 13485:2016 with scope text — confirm it covers your product category (e.g. sterile injectable medical devices). Verify the certificate number against the issuing body online registry.

Distinguish between manufacturer certification and product registration. CE, NMPA, or FDA clearance is product-specific and separate from a factory quality system certificate.

For CE-marked products, the Notified Body number must appear on the label. Cross-check it against the EU NANDO database to confirm current authorization.

Ask for a sample CoA from a recent production lot. A genuine manufacturer can provide this within hours; inability to produce one is a significant red flag.

Understand the sample process: Are samples free or invoiced? What quantity is available? Are samples from production stock or lab batches? Production-stock samples are more representative.

Ask whether the factory has undergone third-party audits (BSI, SGS, TUV) in the past 24 months and whether audit reports are available to qualified buyers.

Request MOQ per SKU and per order. Understand whether MOQ changes for private label vs. catalogue product, and whether partial orders are possible for new clients.

Ask for historical on-time delivery data. Reliable suppliers maintain production schedules documented in their QMS — request the most recent production planning records.

Confirm the supplier export packaging — insulated shippers, gel packs, phase-change materials — and whether they provide validated temperature-excursion reports.

Verify how the supplier handles complaints, non-conforming product, and shipment discrepancies. A clear complaint-handling procedure is a QMS requirement; absence of one signals systemic risk.

MOQ in aesthetic medical supply is driven by batch size economics (minimum viable production run), packaging line setup, and regulatory batch documentation requirements. A 50-unit minimum exists because the CoA and batch record overhead is roughly equal whether you produce 50 or 5,000 units.

Catalogue (stock) products typically have low MOQ — often 1 box — because they share production runs across many buyers. Private label orders carry higher MOQ because each artwork setup, label print run, and batch record is unique to your brand.

Total lead time = production lead time + quality release time + export documentation time + transit time. For air freight to most markets: production 3-8 weeks, QC release 3-5 days, documentation 2-3 days, transit 3-5 days.

Aesthetic treatment volumes spike Q4 (pre-holiday), Q1 (post-New Year), and May-June (pre-summer). Plan purchase orders 10-12 weeks ahead of peak seasons to avoid competing for factory capacity.

Safety stock = (average daily usage x lead time) + buffer. For injectable products with 6-24 month shelf life, holding 8-12 weeks of safety stock is a common benchmark among established clinics.

Monophasic fillers homogenise HA into a single-phase gel during cross-linking — producing a smooth, cohesive texture suitable for fine lines and superficial correction. Biphasic fillers produce a two-phase system (cross-linked particles in a carrier gel) that provides more lift capacity for mid-face volumisation.

BDDE (1,4-butanediol diglycidyl ether) is the industry-standard cross-linker. Degree of modification (DoM) — the percentage of HA disaccharide units bonded to BDDE — determines firmness and longevity. Higher DoM = greater resistance to enzymatic degradation = longer duration.

G-prime is the measure of a gel's resistance to deformation under stress. Higher G-prime products (e.g. G-prime > 400 Pa) are appropriate for structural support (chin, jaw, nose). Lower G-prime products (G-prime < 100 Pa) suit superficial hydration and periorbital work where soft tissue integration matters more than lift.

Most commercial fillers range from 20-24 mg/mL total HA. Concentration alone does not determine performance — the balance between free and cross-linked HA, and particle size distribution, matters equally. Comparing products on mg/mL alone is insufficient.

Upper face (forehead, crow's feet, periorbital): low G-prime, low viscosity. Mid-face (cheeks, nasolabial): medium-high G-prime, cohesive. Lower face (lips, marionette): medium G-prime, high plasticity. Structural (chin, jaw, nose): high G-prime, high cohesivity. Skin boosters: very low HA concentration (1-2 mg/mL), no cross-linking, for intradermal hydration only.

Most HA dermal fillers are labelled store below 25 deg C, protect from freezing. Botulinum toxin preparations require 2-8 deg C refrigerated storage. Exosome and growth factor products may require -20 deg C or -80 deg C frozen storage — verify with the manufacturer before arranging transport.

Pure HA dermal fillers are not classified as dangerous goods and can be shipped as standard air cargo. However, some products contain lidocaine — confirm whether the lidocaine concentration triggers any pharmaceutical air cargo requirements in your destination country.

Dermal fillers: HS 3006.10 or 3002.90 depending on country and product form. Botulinum toxin: HS 3002.20. Thread lifts (PDO/PCL): HS 9018.32. Incorrect classification risks re-classification at customs, duty exposure, and delayed clearance. Engage a licensed customs broker familiar with medical device imports.

Most regulated markets require either a Medical Device Import License, a distributor authorization letter from the manufacturer, or both. AestiSource provides standard authorization letters and technical documentation packages. Country-specific registration requirements vary — see the Regulatory & Compliance guide.

Upon receipt: verify outer packaging integrity, confirm temperature log is within specification, check product expiry dates against your safety stock horizon, and inspect labels against the approved specification. Reject any shipment where the temperature log shows an excursion — even if product appears intact.

Authentic CE-marked HA fillers have a cost floor driven by HA raw material, cross-linking chemistry, sterile fill, QC testing, and certification overhead. Pricing 40-60% below established market benchmarks usually indicates HA degradation, substandard cross-linking, unlicensed manufacturing, or counterfeit branding.

A CoA should include: product name, batch number, manufacturing date, expiry date, specification parameters with actual results and limits, and a quality release signature. Suppliers who provide generic spec sheets instead of batch-specific CoAs have likely not tested the specific lot you received.

A CE mark without a four-digit Notified Body number on the label (and on the certificate) is a self-declaration — valid only for Class I non-sterile devices. Sterile injectables must carry a Notified Body number. Always verify the number against NANDO.

A legitimate supplier actively encourages you to test samples because it builds confidence and reduces post-order disputes. Resistance to providing samples — especially for first-time buyers — warrants caution.

Ask how the supplier handles a non-conforming shipment. A compliant QMS supplier will have a documented CAPA (Corrective and Preventive Action) procedure and will be able to share the process — even if not specific case details.